納米氧化鋅(ZnO-NPs)是直徑在1~100 nm的無(wú)機(jī)材料,具有靶向腫瘤細(xì)胞、對(duì)血液腫瘤細(xì)胞敏感的特性,而對(duì)正常細(xì)胞影響較小,在治療血液腫瘤方面逐漸成為研究熱點(diǎn)。ZnO-NPs通過(guò)阻滯細(xì)胞周期、抑制腫瘤細(xì)胞增殖、調(diào)控線粒體功能、通過(guò)釋放Zn²⁺來(lái)影響細(xì)胞穩(wěn)態(tài)等進(jìn)而誘導(dǎo)腫瘤細(xì)胞凋亡,從而破壞腫瘤細(xì)胞穩(wěn)態(tài);還可增敏化療藥物,并作為生物傳感器,在治療血液腫瘤方面具有很大潛力。對(duì)ZnO-NPs的藥理作用及其在抗白血病、多發(fā)性骨髓瘤、淋巴瘤中的藥理機(jī)制進(jìn)行綜述,以期為優(yōu)化血液腫瘤治療手段提供新策略。

Nano-zinc oxide(ZnO-NPs) is an inorganic material with a diameter of 1-100 nm, which has the characteristics of targeting tumor cells and being sensitive to blood tumor cells, but has little influence on normal cells, and has gradually become a research hotspot in the treatment of blood tumors. ZnO-NPs induces apoptosis by blocking cell cycle, inhibiting the proliferation of tumor cells, regulating mitochondrial function, and releasing Zn²⁺ to affect cell homeostasis, thus destroying the homeostasis of blood tumor cells. It can sensitize chemotherapy drugs and can be used as a biosensor, which has great potential in the treatment of blood tumors. The pharmacological effects of ZnO-NPs and its mechanism in leukemia, multiple myeloma and lymphoma were reviewed in order to provide new strategies for optimizing treatment methods.

R979.1

山東省自然科學(xué)基金資助項(xiàng)目(ZR2020KH023)